Modeling and Simulation - PK/PD Archives | Certara

Publication

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…

Certara2025 年 8 月 13 日

Publication

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial

Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…

Certara2025 年 8 月 13 日

Webinar

理解抗体-药物偶联物（ADCs）的药代动力学：从 NCA 到群体药代动力学（PopPK）方法

Certara2025 年 8 月 1 日

Blog

ADNCA 解析：下一代非房室分析及其核心问题解答

ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…

Certara2025 年 7 月 23 日

On-Demand Webinar

基于云端与人工智能构建药代动力学/药效学工作流程[亚太地区网络研讨会]

Certara2025 年 7 月 15 日

Live Events

Phoenix Roadshow 2025 – Copenhagen

Certara2025 年 7 月 2 日

Blog

参比标度平均生物等效性（Reference-scaled Average Bioequivalence, RSABE）方法

We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…

Certara2025 年 7 月 1 日

Blog

5 大临床开发挑战 — 基于模型的荟萃分析（MBMA）助力应对

2025 年 6 月 30 日 Drug development is increasingly defined by its complexity. Teams must navigate rising…

Certara2025 年 6 月 30 日

Case Study

如何通过模型引导的药物开发助力项目从高风险局面中脱困

Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…

Certara2025 年 6 月 26 日

On-Demand Webinar

从数据到决策：基于模型的荟萃分析（MBMA）与 GSK 和 Certara 真实世界影响

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

Certara2025 年 6 月 18 日

© 2025 Certara. 保留所有权力。 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software